SCHEMBL3224286

SCHEMBL3224286

CCCC(=O)Nc1ccc2nn(-c3ccc(N(CC)CC)cc3)nc2c1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.73
TP53 P04637 4/20 0.73
NPC1 O15118 6/20 0.71
RAB9A P51151 6/20 0.71
MEN1 O00255 3/20 0.60
KMT2A Q03164 3/20 0.60
RORC P51449 1/20 0.60
L3MBTL1 Q9Y468 1/20 0.60
SMN1; SMN2 Q16637 5/20 0.53
RXFP1 Q9HBX9 2/20 0.53
KDM4E B2RXH2 2/20 0.53
ALDH1A1 P00352 2/20 0.53
HPGD P15428 1/20 0.53
NFKB1 P19838 1/20 0.53
NFKB2 Q00653 1/20 0.53
RELA Q04206 1/20 0.53
LMNA P02545 2/20 0.53
CASP3 P42574 1/20 0.48
SENP8 Q96LD8 1/20 0.48
SENP7 Q9BQF6 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3230932 0.93 MAPT (0.64) MAPTTP53NPC1RAB9AMEN1
SCHEMBL3220600 0.91 NPC1 (0.72) MAPTTP53NPC1RAB9AMEN1
SCHEMBL3227976 0.87 NPC1 (0.57) MAPTTP53NPC1RAB9AMEN1
SCHEMBL3219219 0.85 MAPT (0.78) MAPTTP53NPC1RAB9AMEN1
SCHEMBL3225797 0.84 NPC1 (0.71) MAPTTP53NPC1RAB9AMEN1
SCHEMBL3229494 0.83 SMN1; SMN2 (0.73) MAPTTP53NPC1RAB9ASMN1; SMN2
SCHEMBL3210188 0.82 MAPT (0.60) MAPTTP53NPC1RAB9AMEN1
SCHEMBL3224129 0.81 MAPT (0.55) MAPTTP53NPC1RAB9AMEN1
SCHEMBL3224063 0.81 MAPT (0.53) MAPTTP53NPC1RAB9AMEN1
SCHEMBL3219494 0.81 MAPT (0.59) MAPTTP53NPC1RAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100168072-A1 Drug Combinations for the Treatment of Duchenne Muscular Dystrophy BIOMARIN IGA LIMITED 2010-07-01 US claimed
US-20100168072-A1 Drug Combinations for the Treatment of Duchenne Muscular Dystrophy BIOMARIN IGA LIMITED 2010-07-01 US disclosed
EP-2170325-A2 DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY Summit Corporation Plc (GB) 2010-04-07 EP disclosed
US-20100048660-A1 TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY BIOMARIN IGA LIMITED (BS) 2010-02-25 US disclosed
CN-101420952-A Treatment of duchenne muscular dystrophy SUMMIT CORP PLC (GB) 2009-04-29 CN disclosed
WO-2009019505-A2 DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY SUMMIT CORPORATION PLC (GB) 2009-02-12 WO disclosed
EP-1986643-A1 TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY Summit Corporation Plc (GB) 2008-11-05 EP disclosed
WO-2007091107-A1 TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY SUMMIT CORPORATION PLC (GB) 2007-08-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048660-A1 TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY SMN1; SMN2, CPT1B, GYS1 MAPT 4772/4885TP53 4078/4885NPC1 2950/4885
US-20100168072-A1 Drug Combinations for the Treatment of Duchenne Muscular Dystrophy CPT1B, PYGM, MTPN MAPT 2870/4885TP53 4863/4885NPC1 2697/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.